AR103252A1 - Compuestos de quinazolina - Google Patents
Compuestos de quinazolinaInfo
- Publication number
- AR103252A1 AR103252A1 ARP150104262A ARP150104262A AR103252A1 AR 103252 A1 AR103252 A1 AR 103252A1 AR P150104262 A ARP150104262 A AR P150104262A AR P150104262 A ARP150104262 A AR P150104262A AR 103252 A1 AR103252 A1 AR 103252A1
- Authority
- AR
- Argentina
- Prior art keywords
- cycloalkyl
- alkyl
- heteroalkyl
- nrarb
- ora
- Prior art date
Links
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 26
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 25
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 abstract 20
- 229910003827 NRaRb Inorganic materials 0.000 abstract 19
- 229910052736 halogen Inorganic materials 0.000 abstract 11
- 150000002367 halogens Chemical class 0.000 abstract 11
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 4
- -1 -ORa Chemical group 0.000 abstract 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 3
- MPVDXIMFBOLMNW-UHFFFAOYSA-N chembl1615565 Chemical compound OC1=CC=C2C=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1N=NC1=CC=CC=C1 MPVDXIMFBOLMNW-UHFFFAOYSA-N 0.000 abstract 3
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen en el presente documento compuestos de fórmula (1) y tautómeros y sales farmacéuticas de los mismos, composiciones y formulaciones que contienen dichos compuestos y métodos para usar y preparar dichos compuestos. Reivindicación 1: Un compuesto de fórmula (1), en donde Q es un resto de fórmula (2) ó (3); X¹, X², y X³ son cada uno independientemente N o C(R¹¹), provisto que, a lo sumo 2 de X¹, X², y X³ son N; R¹ es -H, -CN, -ORᵃ, -C(O)ORᵃ, halógeno, alquilo C₁₋₆, cicloalquilo C₃₋₁₀, o heteroalquilo C₁₋₆, en donde cada alquilo C₁₋₆, cicloalquilo C₃₋₁₀, y heteroalquilo C₁₋₆ está opcionalmente sustituido con 2, 3, 4, ó 5 Grupos R¹², que pueden ser los mismos o diferentes; R² es -H, -CN, -ORᵃ, -NRᵃRᵇ, -C(O)ORᵃ, halógeno, alquilo C₁₋₆, cicloalquilo C₃₋₁₀, o heteroalquilo C₁₋₆, en donde cada alquilo C₁₋₆, cicloalquilo C₃₋₁₀ y heteroalquilo C₁₋₆ está opcionalmente sustituido con 1, 2, 3, 4, ó 5 Grupos R¹², que pueden ser los mismos o diferentes; R³ es -H, -ORᵃ, -SRᵃ, -NRᵃRᵇ, -NHC(O)NRᵃRᵇ, alquilo C₁₋₆, cicloalquilo C₃₋₁₀, o heteroalquilo C₁₋₆, en donde cada alquilo C₁₋₆, cicloalquilo C₃₋₁₀, y heteroalquilo C₁₋₆ está opcionalmente sustituido con 1, 2, 3, 4, ó 5 Grupos R¹², que pueden ser los mismos o diferentes; R⁴ es -H, -ORᵃ, halógeno, -NO₂, -CN, -NRᵃRᵇ, -NHC(O)NRᵃRᵇ, -OC(O)NRᵃRᵇ, -CH₂C(O)NRᵃRᵇ, alquilo C₁₋₆, cicloalquilo C₃₋₁₀, o heteroalquilo C₁₋₆, en donde cada alquilo C₁₋₆, cicloalquilo C₃₋₁₀, y heteroalquilo C₁₋₆ está opcionalmente sustituido con 1, 2, 3, 4, ó 5 Grupos R¹², que pueden ser los mismos o diferentes; R⁵ es -H, -ORᵃ, halógeno, -NO₂, -CN, -NRᵃRᵇ, -NHC(O)NRᵃRᵇ, -OC(O)NRᵃRᵇ, -CH₂C(O)NRᵃRᵇ, alquilo C₁₋₆, cicloalquilo C₃₋₁₀, o heteroalquilo C₁₋₆, en donde cada alquilo C₁₋₆, cicloalquilo C₃₋₁₀, y heteroalquilo C₁₋₆ está opcionalmente sustituido con 1, 2, 3, 4, ó 5 Grupos R¹², que pueden ser los mismos o diferentes; R⁶ es -H, -ORᵃ, halógeno, -NO₂, -CN, -NRᵃRᵇ, -NHC(O)NRᵃRᵇ, -OC(O)NRᵃRᵇ, -CH₂C(O)NRᵃRᵇ, alquilo C₁₋₆, cicloalquilo C₃₋₁₀, o heteroalquilo C₁₋₃, en donde cada alquilo C₁₋₆, cicloalquilo C₃₋₁₀ y heteroalquilo C₁₋₆ está opcionalmente sustituido con 1, 2, 3, 4, ó 5 Grupos R¹², que pueden ser los mismos o diferentes; R⁷ es alquilo C₁₋₆, cicloalquilo C₃₋₁₀, heteroalquilo C₁₋₆, halógeno, -ORᵃ, -CN, o -NO₂, en donde cada alquilo C₁₋₆, cicloalquilo C₃₋₁₀, y heteroalquilo C₁₋₆ está opcionalmente sustituido con 1, 2, 3, 4, ó 5 Grupos R¹², que pueden ser los mismos o diferentes; R⁸ es alquilo C₁₋₆, cicloalquilo C₃₋₁₀, heteroalquilo C₁₋₃, halógeno, -ORᵃ, -CN, o -NO₂, en donde cada alquilo C₁₋₆, cicloalquilo, C₃₋₁₀, y heteroalquilo C₁₋₆ está opcionalmente sustituido con 1, 2, 3, 4, ó 5 Grupos R¹², que pueden ser los mismos o diferentes; R⁹ es -H, alquilo C₁₋₆, o cicloalquilo C₃₋₁₀, en donde cada alquilo C₁₋₆ y cicloalquilo C₃₋₁₀ está opcionalmente sustituido con 1, 2, 3, 4, ó 5 Grupos R¹², que pueden ser los mismos o diferentes; R¹⁰ es -H, alquilo C₁₋₆, o cicloalquilo C₃₋₁₀, en donde cada alquilo C₁₋₆ y cicloalquilo C₃₋₁₀ está opcionalmente sustituido con 1, 2, 3, 4, ó 5 Grupos R¹², que pueden ser los mismos o diferentes; cada R¹¹ es independientemente -H, -CN, -ORᵃ, -C(O)ORᵃ, halógeno, alquilo C₁₋₆, cicloalquilo C₃₋₁₀, o heteroalquilo C₁₋₆, que, pueden ser los mismos o diferentes, en donde cada alquilo C₁₋₃, cicloalquilo C₃₋₁₀, y heteroalquilo C₁₋₆ está opcionalmente sustituido con 1, 2, 3, 4, ó 5 Grupos R¹², que pueden ser los mismos o diferentes; cada R¹² es independientemente alquilo C₁₋₆, cicloalquilo C₃₋₁₀, heteroalquilo C₁₋₆, heterociclilo de 5 - 10 miembros, arilo C₆₋₁₀, heteroarilo de 5 - 10 miembros, halógeno, -ORᵃ, -C(O)Rᵃ, -C(O)ORᵃ, -C(O)NRᵃRᵇ, -OC(O)NRᵃRᵇ, -NRᵃC(O)ORᵇ, -SRᵃ, -S(O)₁₋₂Rᵃ, -S(O)₂F, -S(O)₂NRᵃRᵇ, -NRᵃS(O)₂Rᵇ, -N₃, -CN, o -NO₂; en donde cada alquilo C₁₋₆, cicloalquilo C₃₋₁₀, heteroalquilo C₁₋₆, y heterociclilo de 5 - 10 miembros está opcionalmente sustituido con 1, 2, 3, 4, ó 5 sustituyentes seleccionados de halógeno, -ORᵃ, -C(O)Rᵃ, -C(O)ORᵃ, -C(O)NRᵃRᵇ, -OC(O)NRᵃRᵇ, -NRᵃC(O)ORᵇ, -SRᵃ, -S(O)₁₋₂Rᵃ, -S(O)₂F, -S(O)₂NRᵃRᵇ, -NRᵃS(O)₂Rᵇ, -N₃, -CN, y -NO₂, grupos, que pueden ser los mismos o diferentes; cada Rᵃ y Rᵇ es independientemente -H, -NH₂, alquilo C₁₋₆, cicloalquilo C₃₋₁₀, heteroalquilo C₁₋₆, heterociclilo de 5 - 10 miembros, arilo C₆₋₁₀, o heteroarilo de 5 - 10 miembros, en donde cada alquilo C₁₋₆, cicloalquilo C₃₋₁₀, heteroalquilo C₁₋₆, heterociclilo de 5 - 10 miembros, arilo C₆₋₁₀, y heteroarilo de 5 - 10 miembros está opcionalmente sustituido con 1, 2, 3, 4, ó 5 grupos R¹³, que pueden ser los mismos o diferentes; o Rᵃ y Rᵇ junto con los átomos a los que están unidos forman un heterociclo de 5 - 10 miembros; y cada R¹³ es independientemente -CN, halógeno, alquilo C₁₋₆, cicloalquilo C₃₋₁₀, heteroalquilo C₁₋₆, o heterociclilo de 5 - 10 miembros; o un tautómero o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462096748P | 2014-12-24 | 2014-12-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103252A1 true AR103252A1 (es) | 2017-04-26 |
Family
ID=55305044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150104262A AR103252A1 (es) | 2014-12-24 | 2015-12-22 | Compuestos de quinazolina |
Country Status (41)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2553449T3 (es) | 2011-07-06 | 2015-12-09 | Gilead Sciences, Inc. | Compuestos para el tratamiento de VIH |
| EP3237397B1 (en) | 2014-12-24 | 2018-11-21 | Gilead Sciences, Inc. | Isoquinoline compounds for the treatment of hiv |
| ES2735087T3 (es) | 2014-12-24 | 2019-12-16 | Gilead Sciences Inc | Compuestos de pirimidina fusionados para el tratamiento de VIH |
| TW202237569A (zh) * | 2014-12-24 | 2022-10-01 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| US20190022116A1 (en) | 2014-12-26 | 2019-01-24 | Emory University | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| CN111793061A (zh) | 2016-08-19 | 2020-10-20 | 吉利德科学公司 | 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物 |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| AR112413A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas sólidas de un inhibidor de la cápside del vih |
| WO2019113462A1 (en) | 2017-12-07 | 2019-06-13 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| KR102587510B1 (ko) | 2018-02-15 | 2023-10-11 | 길리애드 사이언시즈, 인코포레이티드 | 피리딘 유도체 및 hiv 감염을 치료하기 위한 그의 용도 |
| EP3752496B1 (en) | 2018-02-16 | 2023-07-05 | Gilead Sciences, Inc. | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection |
| EP3823621A1 (en) | 2018-07-16 | 2021-05-26 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
| TW202104210A (zh) | 2019-04-17 | 2021-02-01 | 美商基利科學股份有限公司 | Hiv蛋白酶抑制劑 |
| WO2020214647A1 (en) | 2019-04-17 | 2020-10-22 | Gilead Sciences, Inc. | Solid forms of an hiv protease inhibitor |
| CA3157275A1 (en) | 2019-11-26 | 2021-06-03 | Elena BEKERMAN | Capsid inhibitors for the prevention of hiv |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| KR20230005827A (ko) | 2020-04-24 | 2023-01-10 | 스미토모 파마 가부시키가이샤 | 2-헤테로아릴아미노퀴나졸리논 유도체 |
| CN115996925A (zh) | 2020-06-25 | 2023-04-21 | 吉利德科学公司 | 用于治疗hiv的衣壳抑制剂 |
| AU2021377614A1 (en) | 2020-11-11 | 2023-06-22 | Gilead Sciences, Inc. | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES |
| TW202342448A (zh) | 2021-12-03 | 2023-11-01 | 美商基利科學股份有限公司 | 用於ｈｉｖ病毒感染之治療性化合物 |
| TW202342447A (zh) | 2021-12-03 | 2023-11-01 | 美商基利科學股份有限公司 | 用於ｈｉｖ病毒感染之治療性化合物 |
| EP4440702A1 (en) | 2021-12-03 | 2024-10-09 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| TWI843506B (zh) | 2022-04-06 | 2024-05-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| TW202402280A (zh) | 2022-07-01 | 2024-01-16 | 美商基利科學股份有限公司 | 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物 |
| WO2024044477A1 (en) | 2022-08-26 | 2024-02-29 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
| WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| WO2024220624A1 (en) | 2023-04-19 | 2024-10-24 | Gilead Sciences, Inc. | Dosing regimen of capsid inhibitor |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ197420A (en) | 1980-07-01 | 1984-04-27 | Ici Australia Ltd | -(quinazolin-(2-or 4-)(oxy,ylthio or amino)phen(oxy or ylthio)alkanoic acid derivatives |
| JPH11209350A (ja) | 1998-01-26 | 1999-08-03 | Eisai Co Ltd | 含窒素複素環誘導体およびその医薬 |
| WO2001021598A1 (en) | 1999-09-23 | 2001-03-29 | Astrazeneca Ab | Therapeutic quinazoline compounds |
| JP2003514901A (ja) | 1999-11-22 | 2003-04-22 | ワーナー−ランバート・カンパニー | キナゾリン類およびシクリン依存性キナーゼ酵素を阻害するためのその使用 |
| GB0002032D0 (en) | 2000-01-28 | 2000-03-22 | Zeneca Ltd | Chemical compounds |
| WO2002010136A1 (en) | 2000-08-02 | 2002-02-07 | Celltech R & D Limited | 3-substituted isoquinolin-1-yl derivatives |
| CA2422488A1 (en) | 2000-09-20 | 2002-03-28 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | 4-amino-quinazolines |
| WO2004030672A1 (en) | 2002-10-02 | 2004-04-15 | Merck Patent Gmbh | Use of 4 amino-quinazolines as anti cancer agents |
| SG182849A1 (en) | 2003-04-25 | 2012-08-30 | Gilead Sciences Inc | Antiviral phosphonate analogs |
| WO2004108711A1 (en) | 2003-06-05 | 2004-12-16 | Astrazeneca Ab | Pyrazinil quinazoline derivatives for use in the treatment of tumours |
| JP2007008816A (ja) | 2003-10-15 | 2007-01-18 | Ube Ind Ltd | 新規イソキノリン誘導体 |
| US7871991B2 (en) | 2004-07-27 | 2011-01-18 | Gilead Sciences, Inc. | Phosphonate analogs of HIV inhibitor compounds |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| MX2007005159A (es) | 2004-10-29 | 2007-06-26 | Tibotec Pharm Ltd | Derivados de pirimidina biciclicos inhibidores del vih. |
| EP1844023A1 (en) | 2004-12-31 | 2007-10-17 | Sk Chemicals Co., Ltd. | Quinazoline derivatives for the treatment and prevention of diabetes and obesity |
| WO2006099301A2 (en) | 2005-03-10 | 2006-09-21 | The Regents Of The University Of California | Apoptosis inhibitors |
| EP1878727A4 (en) | 2005-04-28 | 2013-11-13 | Kyowa Hakko Kirin Co Ltd | 2-AMINOQUINAZOLINE DERIVATIVES |
| BRPI0613597A2 (pt) | 2005-06-28 | 2011-01-18 | Sanofi Aventis | derivado de isoquinolina como inibidores de rho-quinase |
| ES2423006T3 (es) | 2005-07-26 | 2013-09-17 | Sanofi | Derivados de isoquinolona sustituidos con piperidinilo como inhibidores de la cinasa Rho |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| AU2007211077B2 (en) | 2006-01-27 | 2012-09-20 | Fibrogen, Inc. | Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (HIF) |
| TW200808739A (en) | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
| WO2007125405A2 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| ATE469144T1 (de) | 2006-07-20 | 2010-06-15 | Amgen Inc | Substituierte pyridonverbindungen und anwendungsverfahren |
| US8027888B2 (en) | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
| JPWO2008050808A1 (ja) | 2006-10-24 | 2010-02-25 | 協和発酵キリン株式会社 | ２−アミノキナゾリン誘導体 |
| BRPI0720862A2 (pt) | 2006-12-27 | 2014-02-25 | Sanofi Aventis | Derivados de isoquinolina e isoquinolinona substituídos como inibidores de rho-cinase |
| BRPI0720710A2 (pt) | 2006-12-27 | 2014-12-23 | Sanofi Aventis | Derivados de isoquinolona e isoquinolinona substituídos com cicloalquilamina |
| EP2125745B1 (en) | 2006-12-27 | 2017-02-22 | Sanofi | Cycloalkylamine substituted isoquinolone derivatives |
| US20090004185A1 (en) | 2007-01-11 | 2009-01-01 | Wyeth | Amino-substituted quinazoline derivatives as inhibitors of beta-catenin/tcf-4 pathway and cancer treatment agents |
| MX2009010696A (es) | 2007-04-06 | 2009-10-20 | Novartis Ag | Derivados de 2,6-naftiridina como moduladores de cinasa de proteina. |
| US20090209536A1 (en) | 2007-06-17 | 2009-08-20 | Kalypsys, Inc. | Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
| CA2707418C (en) | 2007-11-16 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| WO2009131173A1 (ja) | 2008-04-23 | 2009-10-29 | 協和発酵キリン株式会社 | 2-アミノキナゾリン誘導体 |
| MX315904B (es) | 2008-05-30 | 2013-11-29 | Amgen Inc | Inhibidores de fosfoinosituro-3 cinasa. |
| GB0812969D0 (en) | 2008-07-15 | 2008-08-20 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| US8573519B2 (en) | 2008-08-15 | 2013-11-05 | Basf Se | Process for producing nanoscale organic solid particles |
| ES2467108T3 (es) | 2008-12-09 | 2014-06-11 | Gilead Sciences, Inc. | Moduladores de receptores tipo toll |
| MX2011007064A (es) | 2008-12-29 | 2012-01-20 | Fovea Pharmaceuticals | Compuestos de quinazolina substituidos. |
| EP2416660B1 (en) | 2009-04-07 | 2014-07-02 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| WO2011035416A1 (en) | 2009-09-25 | 2011-03-31 | Aegera Therapeutics Inc. | Hsp90 modulating compounds, compositions, methods and uses |
| WO2011139637A1 (en) | 2010-05-03 | 2011-11-10 | Philadelphia Health & Education Corporation | Small-molecule modulators of hiv-1 capsid stability and methods thereof |
| TW201210597A (en) | 2010-06-09 | 2012-03-16 | Gilead Sciences Inc | Inhibitors of hepatitis C virus |
| TW201204723A (en) | 2010-06-22 | 2012-02-01 | Fovea Pharmaceuticals | Heterocyclic compounds, their preparation and their therapeutic application |
| US9102617B2 (en) | 2010-06-25 | 2015-08-11 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
| AP2013006707A0 (en) | 2010-07-02 | 2013-02-28 | Gilead Sciences Inc | 2-Quinolinyl-acetic acid derivatives as HIV antiviral compounds |
| CA2802308C (en) | 2010-07-02 | 2018-08-28 | Lianhong Xu | Napht-2-ylacetic acid derivatives to treat aids |
| KR20130141500A (ko) | 2010-09-29 | 2013-12-26 | 크리스탈지노믹스(주) | 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 |
| KR20120038060A (ko) | 2010-10-13 | 2012-04-23 | 롬엔드하스전자재료코리아유한회사 | 신규한 유기 전자재료용 화합물 및 이를 포함하는 유기 전계 발광 소자 |
| JP6026427B2 (ja) | 2010-12-17 | 2016-11-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 置換６，６−縮合窒素複素環化合物及びその使用 |
| WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
| KR20140027295A (ko) | 2011-04-21 | 2014-03-06 | 길리애드 사이언시즈, 인코포레이티드 | 벤조티아졸 화합물 및 이들의 약학적 용도 |
| ES2553449T3 (es) | 2011-07-06 | 2015-12-09 | Gilead Sciences, Inc. | Compuestos para el tratamiento de VIH |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| WO2013091096A1 (en) | 2011-12-20 | 2013-06-27 | Boehringer Ingelheim International Gmbh | Condensed triclyclic compounds as inhibitors of hiv replication |
| CN105121418A (zh) | 2012-04-20 | 2015-12-02 | 吉利德科学公司 | 苯并噻唑-6-基乙酸衍生物及其治疗hiv感染的用途 |
| SI3608325T1 (sl) | 2012-12-21 | 2022-09-30 | Gilead Sciences, Inc. | Policiklične-karbamoilpiridonske spojine in njihova farmacevtska uporaba |
| RU2015131006A (ru) | 2012-12-27 | 2017-01-30 | Джапан Тобакко Инк. | ЗАМЕЩЕННОЕ ПРОИЗВОДНОЕ СПИРОПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В МЕДИЦИНЕ В КАЧЕСТВЕ ИНГИБИТОРА ИНТЕГРАЗЫ ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ) |
| EP2769722A1 (en) | 2013-02-22 | 2014-08-27 | Ruprecht-Karls-Universität Heidelberg | Compounds for use in inhibiting HIV capsid assembly |
| EP2769723A1 (en) | 2013-02-22 | 2014-08-27 | Ruprecht-Karls-Universität Heidelberg | Compounds for use in inhibiting HIV capsid assembly |
| US9914709B2 (en) | 2013-06-21 | 2018-03-13 | Yale University | Compositions and methods of treating HIV-1 infections using same |
| EP3237397B1 (en) | 2014-12-24 | 2018-11-21 | Gilead Sciences, Inc. | Isoquinoline compounds for the treatment of hiv |
| ES2735087T3 (es) | 2014-12-24 | 2019-12-16 | Gilead Sciences Inc | Compuestos de pirimidina fusionados para el tratamiento de VIH |
| TW202237569A (zh) | 2014-12-24 | 2022-10-01 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
-
2015
- 2015-12-18 TW TW111121406A patent/TW202237569A/zh unknown
- 2015-12-18 TW TW104142712A patent/TWI699355B/zh active
- 2015-12-18 TW TW109122699A patent/TWI770552B/zh active
- 2015-12-22 AR ARP150104262A patent/AR103252A1/es unknown
- 2015-12-23 PL PL15832711T patent/PL3237398T3/pl unknown
- 2015-12-23 EP EP18213309.0A patent/EP3521282B1/en active Active
- 2015-12-23 EP EP15832711.4A patent/EP3237398B1/en active Active
- 2015-12-23 MX MX2017008521A patent/MX367574B/es active IP Right Grant
- 2015-12-23 WO PCT/US2015/000460 patent/WO2016105564A1/en active Application Filing
- 2015-12-23 PL PL18213309T patent/PL3521282T3/pl unknown
- 2015-12-23 CN CN201580076616.XA patent/CN107278201B/zh active Active
- 2015-12-23 ES ES21187414T patent/ES2964395T3/es active Active
- 2015-12-23 HR HRP20211543TT patent/HRP20211543T1/hr unknown
- 2015-12-23 SI SI201530560T patent/SI3237398T1/sl unknown
- 2015-12-23 EP EP23196262.2A patent/EP4302830A3/en active Pending
- 2015-12-23 CR CR20170281A patent/CR20170281A/es unknown
- 2015-12-23 PT PT15832711T patent/PT3237398T/pt unknown
- 2015-12-23 EA EA201791256A patent/EA035746B1/ru unknown
- 2015-12-23 LT LTEP18213309.0T patent/LT3521282T/lt unknown
- 2015-12-23 SG SG11201705215PA patent/SG11201705215PA/en unknown
- 2015-12-23 NZ NZ733174A patent/NZ733174A/en unknown
- 2015-12-23 SG SG10202101143VA patent/SG10202101143VA/en unknown
- 2015-12-23 PE PE2017001139A patent/PE20171306A1/es unknown
- 2015-12-23 ES ES18213309T patent/ES2900810T3/es active Active
- 2015-12-23 PL PL21187414.4T patent/PL3960735T3/pl unknown
- 2015-12-23 EP EP21187414.4A patent/EP3960735B1/en active Active
- 2015-12-23 DK DK18213309.0T patent/DK3521282T3/da active
- 2015-12-23 JP JP2017534259A patent/JP6367489B2/ja active Active
- 2015-12-23 KR KR1020177020449A patent/KR102049476B1/ko active IP Right Grant
- 2015-12-23 AU AU2015371198A patent/AU2015371198B2/en active Active
- 2015-12-23 PT PT182133090T patent/PT3521282T/pt unknown
- 2015-12-23 MD MDA20170070A patent/MD4650B1/ro not_active IP Right Cessation
- 2015-12-23 CU CUP2017000089A patent/CU20170089A7/es unknown
- 2015-12-23 HU HUE18213309A patent/HUE058296T2/hu unknown
- 2015-12-23 CN CN202010295176.XA patent/CN111574464A/zh active Pending
- 2015-12-23 EA EA202091115A patent/EA202091115A1/ru unknown
- 2015-12-23 UA UAA201707115A patent/UA117796C2/uk unknown
- 2015-12-23 CA CA2972021A patent/CA2972021C/en active Active
- 2015-12-23 BR BR102015032361-1A patent/BR102015032361B1/pt active IP Right Grant
- 2015-12-23 MA MA048448A patent/MA48448A/fr unknown
- 2015-12-23 US US14/998,042 patent/US9730936B2/en active Active
- 2015-12-23 ES ES15832711T patent/ES2715507T3/es active Active
- 2015-12-23 KR KR1020197034431A patent/KR102288855B1/ko active IP Right Grant
- 2015-12-23 TR TR2019/03672T patent/TR201903672T4/tr unknown
- 2015-12-23 SI SI201531719T patent/SI3521282T1/sl unknown
- 2015-12-23 MY MYPI2017702362A patent/MY189761A/en unknown
-
2017
- 2017-06-21 IL IL25305917A patent/IL253059B/en active IP Right Grant
- 2017-06-22 EC ECIEPI201739611A patent/ECSP17039611A/es unknown
- 2017-06-22 CO CONC2017/0006214A patent/CO2017006214A2/es unknown
- 2017-06-22 CL CL2017001675A patent/CL2017001675A1/es unknown
- 2017-06-22 SV SV2017005471A patent/SV2017005471A/es unknown
- 2017-06-22 DO DO2017000151A patent/DOP2017000151A/es unknown
- 2017-06-23 MX MX2019009932A patent/MX2019009932A/es unknown
- 2017-06-23 PH PH12017501191A patent/PH12017501191B1/en unknown
- 2017-06-24 SA SA517381826A patent/SA517381826B1/ar unknown
- 2017-06-27 US US15/634,527 patent/US10206926B2/en active Active
-
2018
- 2018-03-12 HK HK18103444.6A patent/HK1244001B/zh unknown
- 2018-07-04 JP JP2018127603A patent/JP2018168181A/ja active Pending
-
2019
- 2019-01-04 US US16/239,578 patent/US10548898B2/en active Active
- 2019-09-25 IL IL269635A patent/IL269635B/en active IP Right Grant
- 2019-12-18 US US16/718,311 patent/US11304948B2/en active Active
-
2021
- 2021-11-10 CY CY20211100979T patent/CY1124726T1/el unknown
-
2022
- 2022-03-09 US US17/690,351 patent/US20230043136A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR108875A1 (es) | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g | |
| AR103297A1 (es) | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina | |
| AR108011A1 (es) | Moduladores receptores de estrógenos | |
| AR110922A1 (es) | Compuestos inhibidores del vih | |
| AR103064A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| AR117616A1 (es) | Compuestos anti-vih | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
| AR104025A1 (es) | Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas | |
| AR089489A1 (es) | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas | |
| AR112216A1 (es) | Derivados de azaquinolina | |
| AR107061A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apj | |
| AR100702A1 (es) | Compuestos inhibidores de quinasa de unión tank | |
| AR102492A1 (es) | Cromanos sustituidos y métodos para su uso | |
| AR101189A1 (es) | Heterociclos nitrogenados antiproliferativos y sus métodos de uso | |
| AR097862A1 (es) | Inhibidores de tirosina quinasa de bruton | |
| AR091193A1 (es) | HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg | |
| AR089865A1 (es) | Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
| AR098492A1 (es) | Derivados de purina | |
| AR105875A1 (es) | Derivados de 2-oxo-1,2-dihidropiridina como inhibidores de bromodominio | |
| AR092347A1 (es) | Derivados de azaindol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |